Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07808970

Prospective Stage-Stratified Histopathologic Study and Proposed Disease-Evolution Model of Gluteal Permanent Synthetic Filler Complications

This prospective biospecimen cohort will collect and analyze tissue from adults undergoing clinically indicated surgery for gluteal permanent synthetic filler disease. Two blinded pathologists will score foreign material burden, inflammation, fibrosis, necrosis, vascular and lymphatic injury, and deep-tissue involvement. Histopathologic severity will be compared across clinical-radiologic stages and time since injection. The study will propose a cross-sectional disease-evolution framework and assess the reproducibility of the scoring system.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Participants will be enrolled before clinically indicated biopsy or filler-removal surgery. Exposure history, symptoms, physical findings, and MRI stage will be recorded using standardized forms. During surgery, samples from mapped tissue planes will be collected without extending the planned excision. Two pathologists blinded to clinical stage will independently grade eight tissue-injury domains and generate a composite severity score. Disagreements will undergo adjudication. The study will evaluate associations between tissue findings, time since injection, and clinical-radiologic stage and will use exploratory clustering to identify histopathologic phenotypes. Because participants are sampled at one operation, the resulting model will be described as a proposed cross-sectional natural-history framework.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age 18 years or older.

  • Prior gluteal injection of a permanent or unknown nonresorbable filler.
  • Clinically indicated biopsy or surgical excision yielding tissue suitable for histopathologic evaluation.
  • Available history of approximate injection date and standardized preoperative clinical staging.
  • Written consent for tissue analysis and optional future use of deidentified specimens.

Exclusion criteria

  • Specimen composed only of scar or skin without tissue from the filler-affected region.
  • Insufficient tissue quality for routine histology.
  • Acute bacterial infection that precludes distinction of the underlying chronic tissue response unless infection is itself a prespecified advanced-stage feature.
  • Prior oncologic radiation to the sampled gluteal region.
  • Declined consent for research use of surgical tissue.

Treatment and study plan

Standardized Tissue Sampling During Clinically Indicated Surgery

Procedure

Samples will be obtained from predefined superficial, interface, deep, and visibly abnormal regions without extending the clinically indicated excision. Each sample will be oriented and linked to an MRI/operative map. Linked arm/group(s): Prospective Histopathology Cohort.

Blinded Histopathologic Scoring

Other

Two pathologists will independently grade foreign material burden, granulomatous inflammation, fibrosis, fat necrosis, vascular injury, lymphatic involvement, muscle injury, and skin necrosis on 0-to-3 ordinal scales. The proposed composite ranges from 0 to 24; the manual will be locked before the first analytic read. Linked arm/group(s): Prospective Histopathology Cohort.

Primary outcomes

  1. Composite Histopathologic Severity Score by Clinical-Radiologic Stage

    Time frame: At the index operation and final blinded histopathology assessment of the surgical specimen. 3 months

    Sum of eight prespecified 0-to-3 domain scores: foreign material burden, granulomatous inflammation, fibrosis, fat necrosis, vascular injury, lymphatic involvement, muscle injury, and skin necrosis. Total score ranges from 0 to 24; higher scores indicate more severe tissue injury.

Secondary outcomes

  1. Prevalence of Individual Histopathologic Features

    Time frame: At final histopathology assessment of the index surgical specimen. 3 months

    Proportion of participants with each prespecified feature and distribution of each 0-to-3 domain grade.

Other outcomes

  1. Histopathologic Phenotype Classification

    Time frame: After completion of tissue collection and database lock, using data from the index specimen. 1 year

    Data-driven clusters or latent classes based on the eight domains, integrated with clinical and MRI stage to generate a proposed disease-evolution framework.

Study contacts

Contact information is provided by the study sponsor or research team.

Edison Osorio, MD, Plastic surgeon

CONTACT

[email protected]

+573226140611

Sponsors and collaborators

Lead sponsor

Research Inc

Industry

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Sep 9, 2026
Registry last updated
Sep 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.